Accutar Biotechnology, Inc. announced that the US FDA has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic CRPC.
[Accutar Biotechnology, Inc.]
Sorry, but the selected Zotpress account can't be found.